A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

Results from the phase 3 FINER study demonstrate that ipatasertib plus fulvestrant significantly improves progression-free survival compared to placebo plus fulvestrant in patients with ER+ HER2- metastatic breast cancer whose disease progressed on first-line CDK4/6 inhibitor and aromatase inhibitor therapy. Follow-up analyses are ongoing.